CD8A and neoplasm: To elucidate the specific T cell subtypes and states contributing to the immune responses triggered by our vaccine, we conducted scRNA-seq and TCR-seq analyses on splenic CD8+ T cells that bind to the tier 1 epitope-dextramer, as well as on the entire tumor population.